Central Nervous System Cancers

  • Sameer K. NathEmail author
  • Daniel M. Trifiletti
  • Nicholas G. Zaorsky
  • Chad G. Rusthoven


This chapter discusses the general management of patients with central nervous system tumors, with special focus on principles that guide radiotherapy management. Several key components of radiotherapy and radiosurgery care are discussed.


Glioma Glioblastoma Brain metastases Radiosurgery Stereotactic Spine 


  1. 1.
    Mayo C, Martel MK, Marks LB, et al. Radiation dose-volume effects of optic nerves and chiasm. Int J Radiat Oncol Biol Phys. 2010;76:S28–35.PubMedCrossRefGoogle Scholar
  2. 2.
    Marks LB, Yorke ED, Jackson A, et al. Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys. 2010;76:S10–9.PubMedPubMedCentralCrossRefGoogle Scholar
  3. 3.
    Cancer Genome Atlas Research N, Brat DJ, Verhaak RG, et al. Comprehensive, integrative genomic analysis of diffuse Lower-grade gliomas. N Engl J Med. 2015;372:2481–98.CrossRefGoogle Scholar
  4. 4.
    Eckel-Passow JE, Lachance DH, Molinaro AM, et al. Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors. N Engl J Med. 2015;372:2499–508.PubMedPubMedCentralCrossRefGoogle Scholar
  5. 5.
    Yamada Y, Bilsky MH, Lovelock DM, et al. High-dose, single-fraction image-guided intensity-modulated radiotherapy for metastatic spinal lesions. Int J Radiat Oncol Biol Phys. 2008;71:484–90.PubMedCrossRefGoogle Scholar
  6. 6.
    Parsons JT, Bova FJ, Mendenhall WM, et al. Response of the normal eye to high dose radiotherapy. Oncology (Williston Park). 1996;10:837–47; discussion 847–8, 851–2.Google Scholar
  7. 7.
    Hanna GG, Murray L, Patel R, et al. UK consensus on normal tissue dose constraints for stereotactic radiotherapy. Clin Oncol (R Coll Radiol). 2018;30:5–14.CrossRefGoogle Scholar
  8. 8.
    Benedict SH, Yenice KM, Followill D, et al. Stereotactic body radiation therapy: the report of AAPM Task Group 101. Med Phys. 2010;37:4078–101.PubMedCrossRefGoogle Scholar
  9. 9.
    Kano H, Kondziolka D, Khan A, et al. Predictors of hearing preservation after stereotactic radiosurgery for acoustic neuroma. J Neurosurg. 2009;111:863–73.PubMedCrossRefGoogle Scholar
  10. 10.
    Tamura M, Carron R, Yomo S, et al. Hearing preservation after gamma knife radiosurgery for vestibular schwannomas presenting with high-level hearing. Neurosurgery. 2009;64:289–96; discussion 296.PubMedCrossRefGoogle Scholar
  11. 11.
    Martinez-Monge R, Gomez-Iturriaga A, Cambeiro M, et al. Phase I-II trial of perioperative high-dose-rate brachytherapy in oral cavity and oropharyngeal cancer. Brachytherapy. 2009;8:26–33.PubMedCrossRefGoogle Scholar
  12. 12.
    Cook B DT. Wikibooks Radiation Oncology. Accessed April 2018.
  13. 13.
    Edge S, Byrd D, Compton C, et al. AJCC cancer staging manual. New York: Springer; 2010.Google Scholar
  14. 14.
    Hansen E, Roach M. Handbook of evidence-based radiation oncology. 2nd ed. New York: Springer; 2010.CrossRefGoogle Scholar
  15. 15.
    Hristov B, Lin SH, Christodouleas JP. Radiation oncology – a question based review. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2014.Google Scholar
  16. 16.
    Karim AB, Maat B, Hatlevoll R, et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. Int J Radiat Oncol Biol Phys. 1996;36:549–56.PubMedCrossRefGoogle Scholar
  17. 17.
    Pignatti F, van den Bent M, Curran D, et al. Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol. 2002;20:2076–84.PubMedCrossRefGoogle Scholar
  18. 18.
    Shaw E, Arusell R, Scheithauer B, et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. J Clin Oncol. 2002;20:2267–76.PubMedCrossRefGoogle Scholar
  19. 19.
    Shaw EG, Wang M, Coons SW, et al. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. J Clin Oncol. 2012;30:3065–70.PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    van den Bent MJ, Afra D, de Witte O, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet. 2005;366:985–90.PubMedCrossRefGoogle Scholar
  21. 21.
    Jakola AS, Skjulsvik AJ, Myrmel KS, et al. Surgical resection versus watchful waiting in low-grade gliomas. Ann Oncol. 2017;28:1942–8.PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    Smith JS, Chang EF, Lamborn KR, et al. Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J Clin Oncol. 2008;26:1338–45.PubMedCrossRefGoogle Scholar
  23. 23.
    Buckner JC, Shaw EG, Pugh SL, et al. Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma. N Engl J Med. 2016;374:1344–55.PubMedPubMedCentralCrossRefGoogle Scholar
  24. 24.
    Fisher BJ, Hu C, Macdonald DR, et al. Phase 2 study of temozolomide-based chemoradiation therapy for high-risk low-grade gliomas: preliminary results of Radiation Therapy Oncology Group 0424. Int J Radiat Oncol Biol Phys. 2015;91:497–504.PubMedPubMedCentralCrossRefGoogle Scholar
  25. 25.
    Baumert BG, Hegi ME, van den Bent MJ, et al. Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. Lancet Oncol. 2016;17:1521–32.PubMedPubMedCentralCrossRefGoogle Scholar
  26. 26.
    Cairncross G, Berkey B, Shaw E, et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol. 2006;24:2707–14.PubMedCrossRefGoogle Scholar
  27. 27.
    Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol. 2013;31:337–43.PubMedCrossRefGoogle Scholar
  28. 28.
    DeAngelis LM. Anaplastic glioma: how to prognosticate outcome and choose a treatment strategy. [corrected]. J Clin Oncol. 2009;27:5861–2.PubMedCrossRefGoogle Scholar
  29. 29.
    Roa W, Brasher PM, Bauman G, et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol. 2004;22:1583–8.PubMedCrossRefGoogle Scholar
  30. 30.
    Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10:459–66.PubMedCrossRefGoogle Scholar
  31. 31.
    van den Bent MJ, Carpentier AF, Brandes AA, et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol. 2006;24:2715–22.PubMedCrossRefGoogle Scholar
  32. 32.
    Walker MD, Alexander E Jr, Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg. 1978;49:333–43.CrossRefGoogle Scholar
  33. 33.
    Wick W, Hartmann C, Engel C, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol. 2009;27:5874–80.PubMedCrossRefGoogle Scholar
  34. 34.
    Wick W, Platten M, Meisner C, et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol. 2012;13:707–15.PubMedCrossRefGoogle Scholar
  35. 35.
    Roa W, Kepka L, Kumar N, et al. International Atomic Energy Agency randomized phase III Study of radiation therapy in elderly and/or frail patients with newly diagnosed glioblastoma multiforme. J Clin Oncol. 2015;33:4145–50.PubMedCrossRefGoogle Scholar
  36. 36.
    Brandes AA, Franceschi E, Tosoni A, et al. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol. 2008;26:2192–7.PubMedCrossRefGoogle Scholar
  37. 37.
    Ruben JD, Dally M, Bailey M, et al. Cerebral radiation necrosis: incidence, outcomes, and risk factors with emphasis on radiation parameters and chemotherapy. Int J Radiat Oncol Biol Phys. 2006;65:499–508.PubMedCrossRefGoogle Scholar
  38. 38.
    Hochberg FH, Pruitt A. Assumptions in the radiotherapy of glioblastoma. Neurology. 1980;30:907–11.PubMedCrossRefGoogle Scholar
  39. 39.
    Walker MD, Green SB, Byar DP, et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med. 1980;303:1323–9.CrossRefGoogle Scholar
  40. 40.
    Shapiro WR, Green SB, Burger PC, et al. Randomized trial of three chemotherapy regimens and two radiotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma. Brain Tumor Cooperative Group Trial 8001. J Neurosurg. 1989;71:1–9.PubMedCrossRefGoogle Scholar
  41. 41.
    Selker RG, Shapiro WR, Burger P, et al. The Brain Tumor Cooperative Group NIH Trial 87-01: a randomized comparison of surgery, external radiotherapy, and carmustine versus surgery, interstitial radiotherapy boost, external radiation therapy, and carmustine. Neurosurgery. 2002;51:343–55; discussion 355–7.PubMedCrossRefGoogle Scholar
  42. 42.
    Laperriere NJ, Leung PM, McKenzie S, et al. Randomized study of brachytherapy in the initial management of patients with malignant astrocytoma. Int J Radiat Oncol Biol Phys. 1998;41:1005–11.PubMedCrossRefGoogle Scholar
  43. 43.
    Souhami L, Seiferheld W, Brachman D, et al. Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. Int J Radiat Oncol Biol Phys. 2004;60:853–60.PubMedCrossRefGoogle Scholar
  44. 44.
    Tsien C, Moughan J, Michalski JM, et al. Phase I three-dimensional conformal radiation dose escalation study in newly diagnosed glioblastoma: Radiation Therapy Oncology Group Trial 98-03. Int J Radiat Oncol Biol Phys. 2009;73:699–708.PubMedCrossRefGoogle Scholar
  45. 45.
    Stewart LA. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet. 2002;359:1011–8.PubMedCrossRefGoogle Scholar
  46. 46.
    Stupp R, Taillibert S, Kanner AA, et al. Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial. JAMA. 2015;314:2535–43.PubMedCrossRefGoogle Scholar
  47. 47.
    Hildebrand J, Gorlia T, Kros JM, et al. Adjuvant dibromodulcitol and BCNU chemotherapy in anaplastic astrocytoma: results of a randomised European Organisation for Research and Treatment of Cancer phase III study (EORTC study 26882). Eur J Cancer. 2008;44:1210–6.PubMedCrossRefGoogle Scholar
  48. 48.
    Niyazi M, Brada M, Chalmers AJ, et al. ESTRO-ACROP guideline "target delineation of glioblastomas". Radiother Oncol. 2016;118:35–42.PubMedCrossRefGoogle Scholar
  49. 49.
    Chang S, Zhang P, Cairncross JG, et al. Phase III randomized study of radiation and temozolomide versus radiation and nitrosourea therapy for anaplastic astrocytoma: results of NRG Oncology RTOG 9813. Neuro-Oncology. 2017;19:252–8.PubMedCrossRefGoogle Scholar
  50. 50.
    Cabrera AR, Kirkpatrick JP, Fiveash JB, et al. Radiation therapy for glioblastoma: executive summary of an American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline. Pract Radiat Oncol. 2016;6:217–25.PubMedCrossRefGoogle Scholar
  51. 51.
    Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg. 2001;95:190–8.PubMedCrossRefGoogle Scholar
  52. 52.
    Sanai N, Polley MY, McDermott MW, et al. An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg. 2011;115:3–8.PubMedCrossRefGoogle Scholar
  53. 53.
    Chaichana KL, Jusue-Torres I, Navarro-Ramirez R, et al. Establishing percent resection and residual volume thresholds affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma. Neuro-Oncology. 2014;16:113–22.PubMedCrossRefGoogle Scholar
  54. 54.
    Brown TJ, Brennan MC, Li M, et al. Association of the Extent of Resection With Survival in Glioblastoma: A Systematic Review and Meta-analysis. JAMA Oncol. 2016;2:1460–9.PubMedCrossRefGoogle Scholar
  55. 55.
    Valtonen S, Timonen U, Toivanen P, et al. Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study. Neurosurgery. 1997;41:44–8; discussion 48–9.PubMedCrossRefGoogle Scholar
  56. 56.
    Westphal M, Ram Z, Riddle V, et al. Gliadel wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial. Acta Neurochir (Wien). 2006;148:269–75; discussion 275.CrossRefGoogle Scholar
  57. 57.
    Garside R, Pitt M, Anderson R, et al. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation. Health Technol Assess. 2007;11:iii-iv–x-221.Google Scholar
  58. 58.
    Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV. Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer. 1981;47:649–52.PubMedCrossRefGoogle Scholar
  59. 59.
    Bleehen NM, Stenning SP. A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. The Medical Research Council Brain Tumour Working Party. Br J Cancer. 1991;64:769–74.PubMedPubMedCentralCrossRefGoogle Scholar
  60. 60.
    Cardinale R, Won M, Choucair A, et al. A phase II trial of accelerated radiotherapy using weekly stereotactic conformal boost for supratentorial glioblastoma multiforme: RTOG 0023. Int J Radiat Oncol Biol Phys. 2006;65:1422–8.PubMedCrossRefGoogle Scholar
  61. 61.
    Nelson DF, Diener-West M, Horton J, et al. Combined modality approach to treatment of malignant gliomas--re-evaluation of RTOG 7401/ECOG 1374 with long-term follow-up: a joint study of the Radiation Therapy Oncology Group and the Eastern Cooperative Oncology Group. NCI Monogr. 1988;6:279–84.Google Scholar
  62. 62.
    Nelson DF, Curran WJ Jr, Scott C, et al. Hyperfractionated radiation therapy and bis-chlorethyl nitrosourea in the treatment of malignant glioma--possible advantage observed at 72.0 Gy in 1.2 Gy B.I.D. fractions: report of the Radiation Therapy Oncology Group Protocol 8302. Int J Radiat Oncol Biol Phys. 1993;25:193–207.PubMedCrossRefGoogle Scholar
  63. 63.
    Werner-Wasik M, Scott CB, Nelson DF, et al. Final report of a phase I/II trial of hyperfractionated and accelerated hyperfractionated radiation therapy with carmustine for adults with supratentorial malignant gliomas. Radiation Therapy Oncology Group Study 83-02. Cancer. 1996;77:1535–43.PubMedCrossRefGoogle Scholar
  64. 64.
    Keime-Guibert F, Chinot O, Taillandier L, et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med. 2007;356:1527–35.PubMedCrossRefGoogle Scholar
  65. 65.
    Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997–1003.PubMedCrossRefGoogle Scholar
  66. 66.
    Malmstrom A, Gronberg BH, Marosi C, et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol. 2012;13:916–26.PubMedCrossRefGoogle Scholar
  67. 67.
    Perry JR, Laperriere N, O’Callaghan CJ, et al. Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma. N Engl J Med. 2017;376:1027–37.PubMedCrossRefGoogle Scholar
  68. 68.
    van den Bent MJ, Baumert B, Erridge SC, et al. Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. Lancet. 2017;390:1645–53.PubMedPubMedCentralCrossRefGoogle Scholar
  69. 69.
    Gilbert MR, Wang M, Aldape KD, et al. Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol. 2013;31:4085–91.PubMedPubMedCentralCrossRefGoogle Scholar
  70. 70.
    Rusthoven CG, Koshy M, Sher DJ, et al. Combined-modality therapy with radiation and chemotherapy for elderly patients with glioblastoma in the temozolomide era: a national cancer database analysis. JAMA Neurol. 2016;73:821–8.PubMedCrossRefGoogle Scholar
  71. 71.
    Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014;370:699–708.PubMedPubMedCentralCrossRefGoogle Scholar
  72. 72.
    Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014;370:709–22.PubMedCrossRefGoogle Scholar
  73. 73.
    McDonald MW, Shu HK, Curran WJ Jr, et al. Pattern of failure after limited margin radiotherapy and temozolomide for glioblastoma. Int J Radiat Oncol Biol Phys. 2011;79:130–6.PubMedCrossRefGoogle Scholar
  74. 74.
    Minniti G, Amelio D, Amichetti M, et al. Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide. Radiother Oncol. 2010;97:377–81.PubMedCrossRefGoogle Scholar
  75. 75.
    Gebhardt BJ, Dobelbower MC, Ennis WH, et al. Patterns of failure for glioblastoma multiforme following limited-margin radiation and concurrent temozolomide. Radiat Oncol. 2014;9:130.PubMedPubMedCentralCrossRefGoogle Scholar
  76. 76.
    Paulsson AK, McMullen KP, Peiffer AM, et al. Limited margins using modern radiotherapy techniques does not increase marginal failure rate of glioblastoma. Am J Clin Oncol. 2014;37:177–81.PubMedPubMedCentralCrossRefGoogle Scholar
  77. 77.
    Chang EL, Akyurek S, Avalos T, et al. Evaluation of peritumoral edema in the delineation of radiotherapy clinical target volumes for glioblastoma. Int J Radiat Oncol Biol Phys. 2007;68:144–50.PubMedCrossRefGoogle Scholar
  78. 78.
    Combs SE, Thilmann C, Edler L, et al. Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single institution. J Clin Oncol. 2005;23:8863–9.PubMedCrossRefGoogle Scholar
  79. 79.
    Fogh SE, Andrews DW, Glass J, et al. Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomas. J Clin Oncol. 2010;28:3048–53.PubMedPubMedCentralCrossRefGoogle Scholar
  80. 80.
    Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer. 2012;48:2192–202.PubMedCrossRefGoogle Scholar
  81. 81.
    Shapiro LQ, Beal K, Goenka A, et al. Patterns of failure after concurrent bevacizumab and hypofractionated stereotactic radiation therapy for recurrent high-grade glioma. Int J Radiat Oncol Biol Phys. 2013;85:636–42.PubMedCrossRefGoogle Scholar
  82. 82.
    Vuorinen V, Hinkka S, Farkkila M, et al. Debulking or biopsy of malignant glioma in elderly people – a randomised study. Acta Neurochir. 2003;145:5–10.PubMedCrossRefGoogle Scholar
  83. 83.
    Brem H, Piantadosi S, Burger PC, et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet. 1995;345:1008–12.PubMedCrossRefGoogle Scholar
  84. 84.
    Laperriere N, Zuraw L, Cairncross G, et al. Radiotherapy for newly diagnosed malignant glioma in adults: a systematic review. Radiother Oncol. 2002;64:259–73.PubMedCrossRefGoogle Scholar
  85. 85.
    Stupp R, Taillibert S, Kanner A, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA. 2017;318:2306–16.PubMedPubMedCentralCrossRefGoogle Scholar
  86. 86.
    Cairncross JG, Wang M, Jenkins RB, et al. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. J Clin Oncol. 2014;32:783–90.PubMedPubMedCentralCrossRefGoogle Scholar
  87. 87.
    Abrey LE, Ben-Porat L, Panageas KS, et al. Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol. 2006;24:5711–5.PubMedCrossRefGoogle Scholar
  88. 88.
    DeAngelis LM, Seiferheld W, Schold SC, et al. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. J Clin Oncol. 2002;20:4643–8.PubMedCrossRefGoogle Scholar
  89. 89.
    Laack NN, Ballman KV, Brown PB, et al. Whole-brain radiotherapy and high-dose methylprednisolone for elderly patients with primary central nervous system lymphoma: Results of North Central Cancer Treatment Group (NCCTG) 96-73-51. Int J Radiat Oncol Biol Phys. 2006;65:1429–39.PubMedCrossRefGoogle Scholar
  90. 90.
    Nelson DF, Martz KL, Bonner H, et al. Non-Hodgkin’s lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. Int J Radiat Oncol Biol Phys. 1992;23:9–17.PubMedCrossRefGoogle Scholar
  91. 91.
    Thiel E, Korfel A, Martus P, et al. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol. 2010;11:1036–47.PubMedCrossRefGoogle Scholar
  92. 92.
    Ferreri AJ, Blay JY, Reni M, et al. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol. 2003;21:266–72.PubMedCrossRefGoogle Scholar
  93. 93.
    Nguyen PL, Chakravarti A, Finkelstein DM, et al. Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma. J Clin Oncol. 2005;23:1507–13.PubMedCrossRefGoogle Scholar
  94. 94.
    Murray K, Kun L, Cox J. Primary malignant lymphoma of the central nervous system. Results of treatment of 11 cases and review of the literature. J Neurosurg. 1986;65:600–7.PubMedCrossRefGoogle Scholar
  95. 95.
    Batchelor T, Carson K, O'Neill A, et al. Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. J Clin Oncol. 2003;21:1044–9.PubMedCrossRefGoogle Scholar
  96. 96.
    Gavrilovic IT, Hormigo A, Yahalom J, et al. Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. J Clin Oncol. 2006;24:4570–4.PubMedCrossRefGoogle Scholar
  97. 97.
    Glass J, Won M, Schultz CJ, et al. Phase I and II study of induction chemotherapy with methotrexate, rituximab, and temozolomide, followed by whole-brain radiotherapy and postirradiation temozolomide for primary cns lymphoma: NRG Oncology RTOG 0227. J Clin Oncol. 2016;34:1620–5.PubMedPubMedCentralCrossRefGoogle Scholar
  98. 98.
    Fisher B, Seiferheld W, Schultz C, et al. Secondary analysis of Radiation Therapy Oncology Group study (RTOG) 9310: an intergroup phase II combined modality treatment of primary central nervous system lymphoma. J Neuro-Oncol. 2005;74:201–5.CrossRefGoogle Scholar
  99. 99.
    Hoang-Xuan K, Taillandier L, Chinot O, et al. Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group. J Clin Oncol. 2003;21:2726–31.PubMedCrossRefGoogle Scholar
  100. 100.
    Morris PG, Correa DD, Yahalom J, et al. Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome. J Clin Oncol. 2013;31:3971–9.PubMedPubMedCentralCrossRefGoogle Scholar
  101. 101.
    Illerhaus G, Marks R, Muller F, et al. High-dose methotrexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study. Ann Oncol. 2009;20:319–25.PubMedCrossRefGoogle Scholar
  102. 102.
    Juergens A, Pels H, Rogowski S, et al. Long-term survival with favorable cognitive outcome after chemotherapy in primary central nervous system lymphoma. Ann Neurol. 2010;67:182–9.PubMedCrossRefGoogle Scholar
  103. 103.
    Yahalom J, Illidge T, Specht L, et al. Modern radiation therapy for extranodal lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys. 2015;92:11–31.PubMedCrossRefGoogle Scholar
  104. 104.
    Goldsmith BJ, Wara WM, Wilson CB, et al. Postoperative irradiation for subtotally resected meningiomas. A retrospective analysis of 140 patients treated from 1967 to 1990. J Neurosurg. 1994;80:195–201.PubMedCrossRefGoogle Scholar
  105. 105.
    Olivero WC, Lister JR, Elwood PW. The natural history and growth rate of asymptomatic meningiomas: a review of 60 patients. J Neurosurg. 1995;83:222–4.PubMedCrossRefGoogle Scholar
  106. 106.
    Attia A, Chan MD, Mott RT, et al. Patterns of failure after treatment of atypical meningioma with gamma knife radiosurgery. J Neuro-Oncol. 2012;108:179–85.CrossRefGoogle Scholar
  107. 107.
    Bos D, Poels MM, Adams HH, et al. Prevalence, clinical management, and natural course of incidental findings on brain mr images: the population-based Rotterdam Scan Study. Radiology. 2016;281:507–15.PubMedCrossRefGoogle Scholar
  108. 108.
    Simpson D. The recurrence of intracranial meningiomas after surgical treatment. J Neurol Neurosurg Psychiatry. 1957;20:22–39.PubMedPubMedCentralCrossRefGoogle Scholar
  109. 109.
    Sughrue ME, Kane AJ, Shangari G, et al. Prevalence of previous extracranial malignancies in a series of 1228 patients presenting with meningioma. J Neurosurg. 2010;113:1115–21.PubMedCrossRefGoogle Scholar
  110. 110.
    Oya S, Kawai K, Nakatomi H, et al. Significance of Simpson grading system in modern meningioma surgery: integration of the grade with MIB-1 labeling index as a key to predict the recurrence of WHO Grade I meningiomas. J Neurosurg. 2012;117:121–8.PubMedCrossRefGoogle Scholar
  111. 111.
    Rogers L, Barani I, Chamberlain M, et al. Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review. J Neurosurg. 2015;122:4–23.PubMedPubMedCentralCrossRefGoogle Scholar
  112. 112.
    Sun SQ, Hawasli AH, Huang J, et al. An evidence-based treatment algorithm for the management of WHO Grade II and III meningiomas. Neurosurg Focus. 2015;38:E3.PubMedCrossRefGoogle Scholar
  113. 113.
    Yano S, Kuratsu J, Kumamoto Brain Tumor Research Group. Indications for surgery in patients with asymptomatic meningiomas based on an extensive experience. J Neurosurg. 2006;105:538–43.PubMedCrossRefGoogle Scholar
  114. 114.
    Rogers L, Zhang P, Vogelbaum MA, et al. Intermediate-risk meningioma: initial outcomes from NRG Oncology RTOG 0539. J Neurosurg. 2017;1:1–13.Google Scholar
  115. 115.
    Tanzler E, Morris CG, Kirwan JM, et al. Outcomes of WHO Grade I meningiomas receiving definitive or postoperative radiotherapy. Int J Radiat Oncol Biol Phys. 2011;79:508–13.PubMedCrossRefGoogle Scholar
  116. 116.
    Solda F, Wharram B, De Ieso PB, et al. Long-term efficacy of fractionated radiotherapy for benign meningiomas. Radiother Oncol. 2013;109:330–4.PubMedCrossRefGoogle Scholar
  117. 117.
    Stafford SL, Pollock BE, Foote RL, et al. Meningioma radiosurgery: tumor control, outcomes, and complications among 190 consecutive patients. Neurosurgery. 2001;49:1029–37; discussion 1037–8.PubMedGoogle Scholar
  118. 118.
    Sheehan JP, Cohen-Inbar O, Ruangkanchanasetr R, et al. Post-radiosurgical edema associated with parasagittal and parafalcine meningiomas: a multicenter study. J Neuro-Oncol. 2015;125:317–24.CrossRefGoogle Scholar
  119. 119.
    Fokas E, Henzel M, Surber G, et al. Stereotactic radiation therapy for benign meningioma: long-term outcome in 318 patients. Int J Radiat Oncol Biol Phys. 2014;89:569–75.PubMedCrossRefGoogle Scholar
  120. 120.
    Kondziolka D, Flickinger JC, Perez B. Judicious resection and/or radiosurgery for parasagittal meningiomas: outcomes from a multicenter review. Gamma Knife Meningioma Study Group. Neurosurgery. 1998;43:405–13; discussion 413–4.PubMedCrossRefGoogle Scholar
  121. 121.
    Patil CG, Hoang S, Borchers DJ 3rd, et al. Predictors of peritumoral edema after stereotactic radiosurgery of supratentorial meningiomas. Neurosurgery. 2008;63:435–40; discussion 440–2.PubMedCrossRefGoogle Scholar
  122. 122.
    Marchetti M, Bianchi S, Pinzi V, et al. Multisession radiosurgery for sellar and parasellar benign meningiomas: long-term tumor growth control and visual outcome. Neurosurgery. 2016;78:638–46.PubMedCrossRefGoogle Scholar
  123. 123.
    Navarria P, Pessina F, Cozzi L, et al. Hypofractionated stereotactic radiation therapy in skull base meningiomas. J Neuro-Oncol. 2015;124:283–9.CrossRefGoogle Scholar
  124. 124.
    Paulsen F, Doerr S, Wilhelm H, et al. Fractionated stereotactic radiotherapy in patients with optic nerve sheath meningioma. Int J Radiat Oncol Biol Phys. 2012;82:773–8.PubMedCrossRefGoogle Scholar
  125. 125.
    Milker-Zabel S, Huber P, Schlegel W, et al. Fractionated stereotactic radiation therapy in the management of primary optic nerve sheath meningiomas. J Neuro-Oncol. 2009;94:419–24.CrossRefGoogle Scholar
  126. 126.
    Kondziolka D, Mathieu D, Lunsford LD, et al. Radiosurgery as definitive management of intracranial meningiomas. Neurosurgery. 2008;62:53–8; discussion 58–60.PubMedCrossRefGoogle Scholar
  127. 127.
    Santacroce A, Walier M, Regis J, et al. Long-term tumor control of benign intracranial meningiomas after radiosurgery in a series of 4565 patients. Neurosurgery. 2012;70:32–9; discussion 39.PubMedCrossRefGoogle Scholar
  128. 128.
    Andrews DW, Scott CB, Sperduto PW, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet. 2004;363:1665–72.CrossRefGoogle Scholar
  129. 129.
    Aoyama H, Shirato H, Tago M, et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA. 2006;295:2483–91.PubMedCrossRefGoogle Scholar
  130. 130.
    Chang EL, Wefel JS, Hess KR, et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol. 2009;10:1037–44.PubMedPubMedCentralCrossRefGoogle Scholar
  131. 131.
    Gaspar L, Scott C, Rotman M, et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys. 1997;37:745–51.PubMedCrossRefGoogle Scholar
  132. 132.
    Gelber RD, Larson M, Borgelt BB, et al. Equivalence of radiation schedules for the palliative treatment of brain metastases in patients with favorable prognosis. Cancer. 1981;48:1749–53.PubMedCrossRefGoogle Scholar
  133. 133.
    Kocher M, Soffietti R, Abacioglu U, et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol. 2011;29:134–41.PubMedCrossRefGoogle Scholar
  134. 134.
    Kurtz JM, Gelber R, Brady LW, et al. The palliation of brain metastases in a favorable patient population: a randomized clinical trial by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 1981;7:891–5.PubMedCrossRefGoogle Scholar
  135. 135.
    Patchell RA, Tibbs PA, Regine WF, et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA. 1998;280:1485–9.PubMedCrossRefGoogle Scholar
  136. 136.
    Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med. 1990;322:494–500.PubMedCrossRefGoogle Scholar
  137. 137.
    Minniti G, Scaringi C, Paolini S, et al. Single-fraction versus multifraction (3 × 9 Gy) stereotactic radiosurgery for large (>2 cm) brain metastases: a comparative analysis of local control and risk of radiation-induced brain necrosis. Int J Radiat Oncol Biol Phys. 2016;95(4):1142–8.PubMedCrossRefGoogle Scholar
  138. 138.
    Sneed PK, Suh JH, Goetsch SJ, et al. A multi-institutional review of radiosurgery alone vs. radiosurgery with whole brain radiotherapy as the initial management of brain metastases. Int J Radiat Oncol Biol Phys. 2002;53:519–26.PubMedCrossRefGoogle Scholar
  139. 139.
    Yamamoto M, Serizawa T, Shuto T, et al. Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study. Lancet Oncol. 2014;15:387–95.PubMedCrossRefGoogle Scholar
  140. 140.
    Choi CY, Chang SD, Gibbs IC, et al. Stereotactic radiosurgery of the postoperative resection cavity for brain metastases: prospective evaluation of target margin on tumor control. Int J Radiat Oncol Biol Phys. 2012;84:336–42.PubMedCrossRefGoogle Scholar
  141. 141.
    Brown PD, Jaeckle K, Ballman KV, et al. Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: a randomized clinical trial. JAMA. 2016;316:401–9.PubMedPubMedCentralCrossRefGoogle Scholar
  142. 142.
    Brown PD, Ahluwalia MS, Khan OH, et al. Whole-brain radiotherapy for brain metastases: evolution or revolution? J Clin Oncol. 2017: JCO2017759589.Google Scholar
  143. 143.
    Robin TP, Camidge DR, Stuhr K, et al. Excellent outcomes with radiosurgery for multiple brain metastases in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol. 2018;13(5):715–20.PubMedCrossRefGoogle Scholar
  144. 144.
    Sperduto PW, Berkey B, Gaspar LE, et al. A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database. Int J Radiat Oncol Biol Phys. 2008;70:510–4.PubMedCrossRefGoogle Scholar
  145. 145.
    Sperduto PW, Kased N, Roberge D, et al. Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol. 2012;30:419–25.PubMedCrossRefGoogle Scholar
  146. 146.
    Sperduto PW, Yang TJ, Beal K, et al. Estimating survival in patients with lung cancer and brain metastases: an update of the graded prognostic assessment for lung cancer using molecular markers (Lung-molGPA). JAMA Oncol. 2017;3:827–31.PubMedCrossRefGoogle Scholar
  147. 147.
    Horton J, Baxter DH, Olson KB. The management of metastases to the brain by irradiation and corticosteroids. Am J Roentgenol Radium Therapy, Nucl Med. 1971;111:334–6.CrossRefGoogle Scholar
  148. 148.
    Mulvenna P, Nankivell M, Barton R, et al. Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial. Lancet. 2016;388:2004–14.PubMedPubMedCentralCrossRefGoogle Scholar
  149. 149.
    Vecht CJ, Haaxma-Reiche H, Noordijk EM, et al. Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery? Ann Neurol. 1993;33:583–90.PubMedCrossRefGoogle Scholar
  150. 150.
    Kondziolka D, Patel A, Lunsford LD, et al. Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases. Int J Radiat Oncol Biol Phys. 1999;45:427–34.PubMedCrossRefGoogle Scholar
  151. 151.
    Mintz AH, Kestle J, Rathbone MP, et al. A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis. Cancer. 1996;78:1470–6.PubMedCrossRefGoogle Scholar
  152. 152.
    Soffietti R, Kocher M, Abacioglu UM, et al. A European Organisation for Research and Treatment of Cancer phase III trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery: quality-of-life results. J Clin Oncol. 2013;31:65–72.PubMedPubMedCentralCrossRefGoogle Scholar
  153. 153.
    Shaw E, Scott C, Souhami L, et al. Radiosurgery for the treatment of previously irradiated recurrent primary brain tumors and brain metastases: initial report of radiation therapy oncology group protocol (90-05). Int J Radiat Oncol Biol Phys. 1996;34:647–54.PubMedCrossRefGoogle Scholar
  154. 154.
    Shaw E, Scott C, Souhami L, et al. Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05. Int J Radiat Oncol Biol Phys. 2000;47:291–8.PubMedCrossRefGoogle Scholar
  155. 155.
    Eaton BR, LaRiviere MJ, Kim S, et al. Hypofractionated radiosurgery has a better safety profile than single fraction radiosurgery for large resected brain metastases. J Neuro-Oncol. 2015;123:103–11.CrossRefGoogle Scholar
  156. 156.
    Mahajan A, Ahmed S, McAleer MF, et al. Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial. Lancet Oncol. 2017;18:1040–8.PubMedPubMedCentralCrossRefGoogle Scholar
  157. 157.
    Mok TS, Wu YL, Ahn MJ, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med. 2017;376:629–40.PubMedCrossRefPubMedCentralGoogle Scholar
  158. 158.
    Peters S, Camidge DR, Shaw AT, et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med. 2017;377:829–38.PubMedCrossRefPubMedCentralGoogle Scholar
  159. 159.
    Davies MA, Saiag P, Robert C, et al. Dabrafenib plus trametinib in patients with BRAF(V600)-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. Lancet Oncol. 2017;18:863–73.PubMedPubMedCentralCrossRefGoogle Scholar
  160. 160.
    Brennan C, Yang TJ, Hilden P, et al. A phase 2 trial of stereotactic radiosurgery boost after surgical resection for brain metastases. Int J Radiat Oncol Biol Phys. 2014;88:130–6.PubMedPubMedCentralCrossRefGoogle Scholar
  161. 161.
    Soliman H, Ruschin M, Angelov L, et al. Consensus contouring guidelines for postoperative completely resected cavity stereotactic radiosurgery for brain metastases. Int J Radiat Oncol Biol Phys. 2018;100:436–42.PubMedCrossRefPubMedCentralGoogle Scholar
  162. 162.
    McCollough WM, Marcus RB Jr, Rhoton AL Jr, et al. Long-term follow-up of radiotherapy for pituitary adenoma: the absence of late recurrence after greater than or equal to 4500 cGy. Int J Radiat Oncol Biol Phys. 1991;21:607–14.PubMedCrossRefPubMedCentralGoogle Scholar
  163. 163.
    Lopes MB, Sloan E, Polder J. Mixed gangliocytoma-pituitary adenoma: insights on the pathogenesis of a rare sellar tumor. Am J Surg Pathol. 2017;41:586–95.PubMedCrossRefGoogle Scholar
  164. 164.
    Sheehan JP, Pouratian N, Steiner L, et al. Gamma knife surgery for pituitary adenomas: factors related to radiological and endocrine outcomes. J Neurosurg. 2011;114:303–9.PubMedCrossRefGoogle Scholar
  165. 165.
    Jagannathan J, Sherman JH, Mehta GU, et al. Radiobiology of brain metastasis: applications in stereotactic radiosurgery. Neurosurg Focus. 2007;22:E4.PubMedGoogle Scholar
  166. 166.
    Minniti G, Osti M, Jaffrain-Rea ML, et al. Long-term follow-up results of postoperative radiation therapy for Cushing’s disease. J Neuro-Oncol. 2007;84:79–84.CrossRefGoogle Scholar
  167. 167.
    Sheehan JP, Xu Z, Salvetti DJ, et al. Results of gamma knife surgery for Cushing’s disease. J Neurosurg. 2013;119:1486–92.PubMedCrossRefGoogle Scholar
  168. 168.
    Brochier S, Galland F, Kujas M, et al. Factors predicting relapse of nonfunctioning pituitary macroadenomas after neurosurgery: a study of 142 patients. Eur J Endocrinol. 2010;163:193–200.PubMedCrossRefGoogle Scholar
  169. 169.
    Chang EF, Zada G, Kim S, et al. Long-term recurrence and mortality after surgery and adjuvant radiotherapy for nonfunctional pituitary adenomas. J Neurosurg. 2008;108:736–45.PubMedCrossRefGoogle Scholar
  170. 170.
    Pouratian N, Sheehan J, Jagannathan J, et al. Gamma knife radiosurgery for medically and surgically refractory prolactinomas. Neurosurgery. 2006;59:255–66; discussion 255–66.PubMedCrossRefGoogle Scholar
  171. 171.
    Liu X, Kano H, Kondziolka D, et al. Gamma knife stereotactic radiosurgery for drug resistant or intolerant invasive prolactinomas. Pituitary. 2013;16:68–75.PubMedCrossRefGoogle Scholar
  172. 172.
    Losa M, Gioia L, Picozzi P, et al. The role of stereotactic radiotherapy in patients with growth hormone-secreting pituitary adenoma. J Clin Endocrinol Metab. 2008;93:2546–52.PubMedCrossRefGoogle Scholar
  173. 173.
    Lee CC, Vance ML, Xu Z, et al. Stereotactic radiosurgery for acromegaly. J Clin Endocrinol Metab. 2014;99:1273–81.PubMedCrossRefGoogle Scholar
  174. 174.
    Preston-Martin S, Thomas DC, Wright WE, et al. Noise trauma in the aetiology of acoustic neuromas in men in Los Angeles County, 1978–1985. Br J Cancer. 1989;59:783–6.PubMedPubMedCentralCrossRefGoogle Scholar
  175. 175.
    Matthies C, Samii M. Direct brainstem recording of auditory evoked potentials during vestibular schwannoma resection: nuclear BAEP recording. Technical note and preliminary results. J Neurosurg. 1997;86:1057–62.PubMedCrossRefGoogle Scholar
  176. 176.
    Baschnagel AM, Chen PY, Bojrab D, et al. Hearing preservation in patients with vestibular schwannoma treated with d surgery. J Neurosurg. 2013;118:571–8.PubMedCrossRefGoogle Scholar
  177. 177.
    Plotkin SR, Stemmer-Rachamimov AO, Barker FG 2nd, et al. Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med. 2009;361:358–67.PubMedPubMedCentralCrossRefGoogle Scholar
  178. 178.
    Noren G. Long-term complications following gamma knife radiosurgery of vestibular schwannomas. Stereotact Funct Neurosurg. 1998;70(Suppl 1):65–73.PubMedCrossRefGoogle Scholar
  179. 179.
    Regis J, Pellet W, Delsanti C, et al. Functional outcome after gamma knife surgery or microsurgery for vestibular schwannomas. J Neurosurg. 2002;97:1091–100.PubMedCrossRefGoogle Scholar
  180. 180.
    Pollock BE. Management of vestibular schwannomas that enlarge after stereotactic radiosurgery: treatment recommendations based on a 15 year experience. Neurosurgery. 2006;58:241–8; discussion 241–8.PubMedCrossRefGoogle Scholar
  181. 181.
    Pollock BE, Driscoll CL, Foote RL, et al. Patient outcomes after vestibular schwannoma management: a prospective comparison of microsurgical resection and stereotactic radiosurgery. Neurosurgery. 2006;59:77–85; discussion 77–85.PubMedCrossRefGoogle Scholar
  182. 182.
    Maniakas A, Saliba I. Microsurgery versus stereotactic radiation for small vestibular schwannomas: a meta-analysis of patients with more than 5 years' follow-up. Otol Neurotol. 2012;33:1611–20.PubMedCrossRefGoogle Scholar
  183. 183.
    Lunsford LD, Niranjan A, Flickinger JC, et al. Radiosurgery of vestibular schwannomas: summary of experience in 829 cases. J Neurosurg. 2005;102(Suppl):195–9.PubMedCrossRefGoogle Scholar
  184. 184.
    Meijer OW, Vandertop WP, Baayen JC, et al. Single-fraction vs. fractionated linac-based stereotactic radiosurgery for vestibular schwannoma: a single-institution study. Int J Radiat Oncol Biol Phys. 2003;56:1390–6.PubMedCrossRefGoogle Scholar
  185. 185.
    Andrews DW, Suarez O, Goldman HW, et al. Stereotactic radiosurgery and fractionated stereotactic radiotherapy for the treatment of acoustic schwannomas: comparative observations of 125 patients treated at one institution. Int J Radiat Oncol Biol Phys. 2001;50:1265–78.PubMedCrossRefGoogle Scholar
  186. 186.
    Andrews DW, Werner-Wasik M, Den RB, et al. Toward dose optimization for fractionated stereotactic radiotherapy for acoustic neuromas: comparison of two dose cohorts. Int J Radiat Oncol Biol Phys. 2009;74:419–26.PubMedCrossRefGoogle Scholar
  187. 187.
    Nakamura H, Jokura H, Takahashi K, et al. Serial follow-up MR imaging after gamma knife radiosurgery for vestibular schwannoma. AJNR Am J Neuroradiol. 2000;21:1540–6.PubMedGoogle Scholar
  188. 188.
    Agrawal Y, Clark JH, Limb CJ, et al. Predictors of vestibular schwannoma growth and clinical implications. Otol Neurotol. 2010;31:807–12.PubMedCrossRefGoogle Scholar
  189. 189.
    Matthies C, Samii M. Management of 1000 vestibular schwannomas (acoustic neuromas): clinical presentation. Neurosurgery. 1997;40:1–9; discussion 9–10.PubMedGoogle Scholar
  190. 190.
    Carlson ML, Vivas EX, McCracken DJ, et al. Congress of neurological surgeons systematic review and evidence-based guidelines on hearing preservation outcomes in patients with sporadic vestibular schwannomas. Neurosurgery. 2018;82:E35–9.PubMedCrossRefGoogle Scholar
  191. 191.
    Myrseth E, Moller P, Pedersen PH, et al. Vestibular schwannoma: surgery or gamma knife radiosurgery? A prospective, nonrandomized study. Neurosurgery. 2009;64:654–61; discussion 661–3.PubMedCrossRefGoogle Scholar
  192. 192.
    Germano IM, Sheehan J, Parish J, et al. Congress of neurological surgeons systematic review and evidence-based guidelines on the role of radiosurgery and radiation therapy in the management of patients with vestibular schwannomas. Neurosurgery. 2018;82:E49–51.PubMedCrossRefGoogle Scholar
  193. 193.
    Sughrue ME, Yang I, Aranda D, et al. The natural history of untreated sporadic vestibular schwannomas: a comprehensive review of hearing outcomes. J Neurosurg. 2010;112:163–7.PubMedCrossRefGoogle Scholar
  194. 194.
    Sughrue ME, Kane AJ, Kaur R, et al. A prospective study of hearing preservation in untreated vestibular schwannomas. J Neurosurg. 2011;114:381–5.PubMedCrossRefGoogle Scholar
  195. 195.
    Stangerup SE, Thomsen J, Tos M, et al. Long-term hearing preservation in vestibular schwannoma. Otol Neurotol. 2010;31:271–5.PubMedCrossRefGoogle Scholar
  196. 196.
    Ferri GG, Modugno GC, Pirodda A, et al. Conservative management of vestibular schwannomas: an effective strategy. Laryngoscope. 2008;118:951–7.PubMedCrossRefGoogle Scholar
  197. 197.
    Barker FG 2nd, Carter BS, Ojemann RG, et al. Surgical excision of acoustic neuroma: patient outcome and provider caseload. Laryngoscope. 2003;113:1332–43.PubMedCrossRefGoogle Scholar
  198. 198.
    Tsao MN, Sahgal A, Xu W, et al. Stereotactic radiosurgery for vestibular schwannoma: International Stereotactic Radiosurgery Society (ISRS) practice guideline. J Radiosurg SBRT. 2017;5:5–24.PubMedPubMedCentralGoogle Scholar
  199. 199.
    Regis J, Carron R, Park MC, et al. Wait-and-see strategy compared with proactive gamma knife surgery in patients with intracanalicular vestibular schwannomas: clinical article. J Neurosurg. 2013;119(Suppl):105–11.PubMedGoogle Scholar
  200. 200.
    Breivik CN, Nilsen RM, Myrseth E, et al. Conservative management or gamma knife radiosurgery for vestibular schwannoma: tumor growth, symptoms, and quality of life. Neurosurgery. 2013;73:48–56; discussion 56–7.PubMedCrossRefGoogle Scholar
  201. 201.
    Hansasuta A, Choi CY, Gibbs IC, et al. Multisession stereotactic radiosurgery for vestibular schwannomas: single-institution experience with 383 cases. Neurosurgery. 2011;69:1200–9.PubMedCrossRefGoogle Scholar
  202. 202.
    Puataweepong P, Dhanachai M, Dangprasert S, et al. Linac-based stereotactic radiosurgery and fractionated stereotactic radiotherapy for vestibular schwannomas: comparative observations of 139 patients treated at a single institution. J Radiat Res. 2014;55:351–8.PubMedCrossRefGoogle Scholar
  203. 203.
    Yomo S, Carron R, Thomassin JM, et al. Longitudinal analysis of hearing before and after radiosurgery for vestibular schwannoma. J Neurosurg. 2012;117:877–85.PubMedCrossRefGoogle Scholar
  204. 204.
    Badakhshi H, Muellner S, Wiener E, et al. Image-guided stereotactic radiotherapy for patients with vestibular schwannoma. A clinical study. Strahlenther Onkol. 2014;190:533–7.PubMedCrossRefGoogle Scholar
  205. 205.
    Spiegelmann R, Lidar Z, Gofman J, et al. Linear accelerator radiosurgery for vestibular schwannoma. J Neurosurg. 2001;94:7–13.PubMedCrossRefGoogle Scholar
  206. 206.
    Kondziolka D, Lunsford LD, McLaughlin MR, et al. Long-term outcomes after radiosurgery for acoustic neuromas. N Engl J Med. 1998;339:1426–33.PubMedCrossRefGoogle Scholar
  207. 207.
    Akpinar B, Mousavi SH, McDowell MM, et al. Early radiosurgery improves hearing preservation in vestibular schwannoma patients with normal hearing at the time of diagnosis. Int J Radiat Oncol Biol Phys. 2016;95:729–34.PubMedCrossRefGoogle Scholar
  208. 208.
    Lopez BC, Hamlyn PJ, Zakrzewska JM. Stereotactic radiosurgery for primary trigeminal neuralgia: state of the evidence and recommendations for future reports. J Neurol Neurosurg Psychiatry. 2004;75:1019–24.PubMedPubMedCentralCrossRefGoogle Scholar
  209. 209.
    Flickinger JC, Pollock BE, Kondziolka D, et al. Does increased nerve length within the treatment volume improve trigeminal neuralgia radiosurgery? A prospective double-blind, randomized study. Int J Radiat Oncol Biol Phys. 2001;51:449–54.PubMedCrossRefGoogle Scholar
  210. 210.
    Maesawa S, Salame C, Flickinger JC, et al. Clinical outcomes after stereotactic radiosurgery for idiopathic trigeminal neuralgia. J Neurosurg. 2001;94:14–20.PubMedCrossRefGoogle Scholar
  211. 211.
    Herman JM, Petit JH, Amin P, et al. Repeat gamma knife radiosurgery for refractory or recurrent trigeminal neuralgia: treatment outcomes and quality-of-life assessment. Int J Radiat Oncol Biol Phys. 2004;59:112–6.PubMedCrossRefGoogle Scholar
  212. 212.
    Pollock BE, Foote RL, Link MJ, et al. Repeat radiosurgery for idiopathic trigeminal neuralgia. Int J Radiat Oncol Biol Phys. 2005;61:192–5.PubMedCrossRefGoogle Scholar
  213. 213.
    Hasegawa T, Kondziolka D, Spiro R, et al. Repeat radiosurgery for refractory trigeminal neuralgia. Neurosurgery. 2002;50:494–500; discussion 500–2.PubMedGoogle Scholar
  214. 214.
    Taich ZJ, Goetsch SJ, Monaco E, et al. Stereotactic radiosurgery treatment of trigeminal neuralgia: clinical outcomes and prognostic factors. World Neurosurg. 2016;90:604–612 e11.PubMedCrossRefGoogle Scholar
  215. 215.
    Maruyama K, Kawahara N, Shin M, et al. The risk of hemorrhage after radiosurgery for cerebral arteriovenous malformations. N Engl J Med. 2005;352:146–53.PubMedCrossRefGoogle Scholar
  216. 216.
    Friedman WA, Bova FJ, Mendenhall WM. Linear accelerator radiosurgery for arteriovenous malformations: the relationship of size to outcome. J Neurosurg. 1995;82:180–9.PubMedCrossRefGoogle Scholar
  217. 217.
    Spetzler RF, Martin NA. A proposed grading system for arteriovenous malformations. J Neurosurg. 1986;65:476–83.PubMedCrossRefGoogle Scholar
  218. 218.
    Mohr JP, Parides MK, Stapf C, et al. Medical management with or without interventional therapy for unruptured brain arteriovenous malformations (ARUBA): a multicentre, non-blinded, randomised trial. Lancet. 2014;383:614–21.PubMedCrossRefGoogle Scholar
  219. 219.
    Kano H, Kondziolka D, Flickinger JC, et al. Stereotactic radiosurgery for arteriovenous malformations, Part 6: multistaged volumetric management of large arteriovenous malformations. J Neurosurg. 2012;116:54–65.PubMedCrossRefGoogle Scholar
  220. 220.
    Kano H, Flickinger JC, Tonetti D, et al. Estimating the risks of adverse radiation effects after gamma knife radiosurgery for arteriovenous malformations. Stroke. 2017;48:84–90.PubMedCrossRefGoogle Scholar
  221. 221.
    Moosa S, Chen CJ, Ding D, et al. Volume-staged versus dose-staged radiosurgery outcomes for large intracranial arteriovenous malformations. Neurosurg Focus. 2014;37:E18.PubMedCrossRefGoogle Scholar
  222. 222.
    Spina A, Boari N, Gagliardi F, et al. The current role of gamma knife radiosurgery in the management of intracranial haemangiopericytoma. Acta Neurochir. 2016;158:635–42.PubMedCrossRefGoogle Scholar
  223. 223.
    Cohen-Inbar O, Lee CC, Mousavi SH, et al. Stereotactic radiosurgery for intracranial hemangiopericytomas: a multicenter study. J Neurosurg. 2017;126:744–54.PubMedCrossRefGoogle Scholar
  224. 224.
    Staples JJ, Robinson RA, Wen BC, et al. Hemangiopericytoma--the role of radiotherapy. Int J Radiat Oncol Biol Phys. 1990;19:445–51.PubMedCrossRefGoogle Scholar
  225. 225.
    Schiariti M, Goetz P, El-Maghraby H, et al. Hemangiopericytoma: long-term outcome revisited. Clinical article. J Neurosurg. 2011;114:747–55.PubMedCrossRefGoogle Scholar
  226. 226.
    Rutkowski MJ, Jian BJ, Bloch O, et al. Intracranial hemangiopericytoma: clinical experience and treatment considerations in a modern series of 40 adult patients. Cancer. 2012;118:1628–36.PubMedCrossRefGoogle Scholar
  227. 227.
    Soyuer S, Chang EL, Selek U, et al. Intracranial meningeal hemangiopericytoma: the role of radiotherapy: report of 29 cases and review of the literature. Cancer. 2004;100:1491–7.PubMedCrossRefGoogle Scholar
  228. 228.
    Gorman CA, Garrity JA, Fatourechi V, et al. A prospective, randomized, double-blind, placebo-controlled study of orbital radiotherapy for Graves’ ophthalmopathy. Ophthalmology. 2001;108:1523–34.PubMedCrossRefGoogle Scholar
  229. 229.
    Prummel MF, Mourits MP, Blank L, et al. Randomized double-blind trial of prednisone versus radiotherapy in Graves' ophthalmopathy. Lancet. 1993;342:949–54.PubMedCrossRefGoogle Scholar
  230. 230.
    Prummel MF, Terwee CB, Gerding MN, et al. A randomized controlled trial of orbital radiotherapy versus sham irradiation in patients with mild Graves’ ophthalmopathy. J Clin Endocrinol Metab. 2004;89:15–20.PubMedCrossRefGoogle Scholar
  231. 231.
    Bartalena L, Baldeschi L, Boboridis K, et al. The 2016 European Thyroid Association/European Group on Graves’ orbitopathy guidelines for the management of Graves’ orbitopathy. Eur Thyroid J. 2016;5:9–26.PubMedPubMedCentralCrossRefGoogle Scholar
  232. 232.
    Mourits MP, van Kempen-Harteveld ML, Garcia MB, et al. Radiotherapy for Graves’ orbitopathy: randomised placebo-controlled study. Lancet. 2000;355:1505–9.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Sameer K. Nath
    • 1
    Email author
  • Daniel M. Trifiletti
    • 2
  • Nicholas G. Zaorsky
    • 3
  • Chad G. Rusthoven
    • 1
  1. 1.University of Colorado School of MedicineAuroraUSA
  2. 2.Mayo ClinicJacksonvilleUSA
  3. 3.Penn State Cancer InstituteHersheyUSA

Personalised recommendations